BNOX

Neuphoria Therapeutics Stock Price

Symbol: NasdaqGM:BNOXMarket Cap: US$3.0mCategory: Pharmaceuticals & Biotech

BNOX Share Price Performance

US$0.25
-0.28 (-52.59%)
US$0.25
-0.28 (-52.59%)
Price US$0.25

BNOX Community Narratives

There are no narratives available yet.

BNOX Community Fair Values

    Recent BNOX News & Updates

    No updates

    Neuphoria Therapeutics Inc. Key Details

    US$0

    Revenue

    US$0

    Cost of Revenue

    US$0

    Gross Profit

    US$10.8m

    Other Expenses

    -US$10.8m

    Earnings

    Last Reported Earnings
    Sep 30, 2024
    Next Reporting Earnings
    n/a
    Earnings per share (EPS)
    0
    Gross Margin
    0%
    Net Profit Margin
    0%
    Debt/Equity Ratio
    0%

    Neuphoria Therapeutics Inc. Competitors

     
     
     
     
     
     
     
     
     
     
     
     

    About BNOX

    Founded
    1996
    Employees
    16
    CEO
    Spyridon Papapetropoulos
    WebsiteView website
    www.bionomics.com.au

    Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7, which is in phase 3 clinical trial for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. In addition, it develops NextGen, which is in preclinical trial for the treatment of multiple central nervous system indications; Kv3.1/3.2 agonist, which is in preclinical trial to treat potential cognitive deficits and negative symptoms/social withdrawal in schizophrenia and autism spectrum disorders; and Nav1.7/1.8 inhibitors which is in preclinical trial for the potential treatment of chronic pain without the liability of addiction associated with opioid treatment. The company has a collaboration with Merck & Co., Inc. to develop a7 receptor positive allosteric modulators targeting cognitive dysfunction associated with alzheimer’s disease and other central nervous system conditions. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.

    Australian Market Performance

    • 7 Days: -0.4%
    • 3 Months: 6.8%
    • 1 Year: 13.2%
    • Year to Date: 5.2%
    Over the last 7 days, the market has remained flat, although notably the Materials sector declined by 4.2%. As for the longer term, the market has risen 8.6% in the past 12 months. Earnings are forecast to grow by 11% annually. Market details ›
    This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
    Continue reading